

IN THE CLAIMS:

Please cancel claims 1-4, 10-14 and 16-17, amend claims 5-9 and 15, and add new claims 18-31 as set forth in the Listing of Claims which replaces all prior versions, and listings, of claims in the application as follows:

**Listing of Claims:**

1. (Cancelled).

2. (Cancelled).

3. (Cancelled).

4. (Cancelled).

5. (Currently amended) The compound or a tautomer, solvate or pharmaceutically acceptable salt thereof according to claim [[1]]18, wherein Ar is selected from phenyl and naphthyl.

6. (Currently amended) The compound or a tautomer, solvate or pharmaceutically acceptable salt thereof according to claim [[1]]18, wherein Z is selected from -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>2</sub>-, -(CH<sub>2</sub>)<sub>3</sub>-, -(CH<sub>2</sub>)<sub>4</sub>-, -(CH<sub>2</sub>)<sub>5</sub>-, -(CH<sub>2</sub>)<sub>6</sub>-, and -(CH<sub>2</sub>)<sub>7</sub>- and *trans*-2-cyclohexylene.

7. (Currently amended) The compound or a tautomer, solvate or pharmaceutically acceptable salt thereof according to claim [[1]]18, wherein R<sub>6</sub> is selected from isopropyl, cyclopentyl, cyclohexyl, phenyl, 4-*n*-butylphenyl, 4-isopropylphenyl and 2-naphthyl.

8. (Currently amended) The compound or a tautomer, solvate or pharmaceutically acceptable salt thereof according to claim [[1]]18, wherein R<sub>2</sub> and R<sub>3</sub> are independently selected from H and 4-chlorobenzyl.

9. (Currently amended) The compound or a tautomer, solvate or pharmaceutically acceptable salt thereof according to claim [[1]]18, wherein the compound is selected from a group consisting of:

4-[3-phenyl-1-(6-phenylhexyl)ureido]butyramide;  
4-[1-(4-butylbenzyl)-3-phenylureido]butyramide;  
4-[1-(4-isopropylbenzyl)-3-phenylureido]butyramide;  
4-[1-(4-methylpentyl)-3-phenylureido]butyramide;  
*N*-(4-chlorobenzyl)-4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide;  
*trans*-2-[1-(3-cyclohexylpropyl)-3-phenylureido]cyclohexanecarboxamide;  
4-[1-(3-cyclohexylpropyl)-3-naphthalen-2-yl-ureido]butyramide;  
4-[1-(2-naphthalen-2-yl-ethyl)-3-phenylureido]butyramide;  
4-[1-(2-cyclohexylethyl)-3-phenylureido]butyramide;  
4-(1-phenethyl-3-phenylureido)butyramide;  
4-(1-benzyl-3-phenylureido)butyramide;  
4-[1-(3-cyclopentylpropyl)-3-phenylureido]butyramide;  
4-[3-phenyl-1-(5-phenylpentyl)ureido]butyramide; and  
4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide.

10. (Cancelled).

11. (Cancelled).

12. (Cancelled).

13. (Cancelled).


14. (Cancelled).

15. (Currently amended) A pharmaceutical composition comprising the compound or a tautomer, solvate or pharmaceutically acceptable salt thereof according to claim [[1]]<sup>18</sup> as active ingredient in association with and a pharmaceutically acceptable adjuvant, diluent or carrier.

16. (Cancelled).

17. (Cancelled).

18. (New) A compound having the formula:



wherein

Z' is  $-(CH_2)_3-$  or cyclohexyl;

Z is selected from a C<sub>1-7</sub> straight or branched chain alkyl, a C<sub>4-8</sub> branched alkylene chain, and a C<sub>2-7</sub> alkenylene chain;

Ar is an aryl group independently selected from an aromatic carbocyclic ring system, a five- or six-membered heteroaromatic ring system and a bicyclic heteroaromatic ring system;

R<sub>3</sub> is selected from a group of substituents (a)-(d) consisting of:

- (a) H;
- (b) C<sub>1-6</sub> straight chain or C<sub>4-8</sub> branched chain alkyl;
- (c) C<sub>3-8</sub> cycloalkyl or C<sub>5-8</sub> cycloalkenyl; and
- (d) C<sub>2-6</sub> alkenyl or alkynyl;

wherein the substituents (b)-(d) optionally have at least one substituent independently selected from a group (e)-(i) consisting of:

- (e) Ar, -O-Ar or -S-Ar;
- (f) OH, O-alkyl or S-alkyl, where alkyl is selected from the substituents (b)-(c);
- (g) -NR<sub>4</sub>R<sub>5</sub>, where R<sub>4</sub> and R<sub>5</sub> are independently selected from the substituents (a)-(d) or optionally together form a nitrogen containing ring structure comprising from 2 to 5 carbon atoms;
- (h) -NH—C(O)-alkyl, -C(O)-alkyl, -O—C(O)-alkyl or -S—C(O)-alkyl, where alkyl is selected from the substituents (b)-(c); and
- (i) F, Cl or Br;

R<sub>6</sub> is selected from a group consisting of Ar and the substituents (a)-(c), where (b) and (c) are optionally substituted with at least one of the substituents (e)-(i);

Ar optionally has at least one substituent independently selected from the substituents (b)-(i);

or

a tautomer, solvate or pharmaceutically acceptable salt of said compound.

19. (New) The compound according to claim 5, wherein Ar is phenyl.

20. (New) The compound according to claim 6, wherein Ar is phenyl.

21. (New) The compound according to claim 6, wherein Z is a C<sub>2-7</sub> straight chain alkyl.

22. (New) The compound according to claim 6, wherein Z is selected from the group consisting of -(CH<sub>2</sub>)-, -(CH<sub>2</sub>)<sub>2</sub>-, -(CH<sub>2</sub>)<sub>3</sub>- and -(CH<sub>2</sub>)<sub>5</sub>-.

23. (New) The compound according to claim 6, wherein Z is -(CH<sub>2</sub>)-.

24. (New) The compound according to claim 5, wherein R<sub>6</sub> is C<sub>3-8</sub> cycloalkyl.

25. (New) The compound according to claim 6, wherein R<sub>6</sub> is C<sub>3-8</sub> cycloalkyl.

26. (New) The compound according to claim 25, wherein R<sub>6</sub> is cyclohexyl.

27. (New) The compound according to claim 5, wherein R<sub>3</sub> is H, C<sub>1-6</sub> straight or C<sub>4-8</sub> branched chain alkyl.

28. (New) The compound according to claim 6, wherein R<sub>3</sub> is H, C<sub>1-6</sub> straight chain or C<sub>4-8</sub> branched chain alkyl.

29. (New) The compound according to claim 28, wherein R<sub>3</sub> is H.

30. (New) The compound according to claim 20, wherein R<sub>6</sub> is C<sub>3-8</sub> cycloalkyl.

31. (New) The compound according to claim 30, wherein R<sub>6</sub> is cyclohexyl.